1. Medtech Insight
  2. >>Business
  3. >>R&D

Boston Scientific Advances First ‘Modular’ Cardiac Rhythm Management System

 
• By Reed Miller

The MODULAR ATP clinical trial has begun to enroll patients to evaluate the safety, performance and effectiveness of Boston Scientific’s mCRM modular therapy system, which includes the Emblem MRI S-ICD and the Empower MPS leadless pacemaker.

Empower S-ICD
Boston Scientific's S-ICD and Empower MPS • Source: Boston Scientific

Boston Scientific is confident it will be the first company to offer a “modular” cardiac rhythm management (mCRM) system with a separate pacemaker and implantable cardioverter defibrillator (ICD) that can wirelessly communicate with each other and work together to manage arrhythmias.

Boston Scientific’s mCRM System consists of its established Emblem MRI subcutaneous implantable defibrillator (S-ICD) system and its Empower MPS leadless...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Boston Scientific Raises Outlook … Again: Headwinds Offset By EP And Watchman

 
• By Natasha Barrow

Agent drug coated balloon, Watchman product sales, and electrophysiology (EP) business unit growth offset Acurate discontinuation and tariff headwinds. CEO Michael Mahoney shouted out coronary therapies business and answered questions on CMS proposed Ambulatory Surgical Center codes.

FDA ‘Regulatory Accelerator’ Aims To Speed Digital Health Development

 
• By Elizabeth Orr

The US FDA has launched the Regulatory Accelerator to expedite digital health product development. This includes resources like a Resource Index for Innovators, a Medical Device Software Guidance Navigator, and best practices for early meetings.

Opinion: Catch A Fraudulent Scientist -- If You Can

 
• By Ivor Campbell

As AI tools make research fraud and résumé fraud easier than ever, life sciences companies need to take steps to protect themselves. Snedden Campbell CEO Ivor Campbell has some tips on successful strategies.

Rising Oncology Start-ups Recognized For Breakthrough Cancer Research

 
• By Natasha Barrow

The Cancer Research Horizons Innovation Awards took place on July 10. Medtech Insight spoke to nominees for the women’s entrepreneur of the year award: Mireia Crispin-Ortuzar, CEO of 52 North Health; Anita Grigoriadis, CEO of PharosAI; and Maria Giovanna Lizio, Founder of WILD-Imaging Technology.

More from Business

Intuitive Surgical Sees Early Wins With Da Vinci 5, Lifts FY25 Guidance As Tariff Impact Eases

 
• By Shubham Singh

For the full year, the company now expects tariffs to increase the cost of sales by approximately 1% of revenue, plus or minus 20 basis points. This is lower than the previous estimate of approximately 1.7% of revenue. The updated gross margin guidance for 2025 is 66%-67%, up from 65%-66.5%.

Private Equity Firm Archimed To Buy ZimVie As Antitrust Concerns Sideline Strategic Buyers

 
• By Marion Webb

Archimed will acquire dental implant firm ZimVie for $730m in a deal that reflects private equity’s growing role in medtech M&A, as strategic buyers face antitrust scrutiny. The deal includes a 125% premium and a 40-day window for competing offers.

Opinion: Catch A Fraudulent Scientist -- If You Can

 
• By Ivor Campbell

As AI tools make research fraud and résumé fraud easier than ever, life sciences companies need to take steps to protect themselves. Snedden Campbell CEO Ivor Campbell has some tips on successful strategies.